Call for Papers

Article List

Editorial [ Hot Topic: Antidepressant Drug Design (Executive Editor: Lee E. Schechter)]
[ Vol. 11 , Issue. 2 ]
Author(s): Lee E. Schechter
Pages: 143-144 (2)
Increasing Hippocampal Neurogenesis: A Novel Mechanism for Antidepressant Drugs
[ Vol. 11 , Issue. 2 ]
Author(s): Jessica E. Malberg and Lee E. Schechter
Pages: 145-155 (11)
Opportunities to Discover Genes Regulating Depression and Antidepressant Response from Rodent Behavioral Genetics
[ Vol. 11 , Issue. 2 ]
Author(s): James J. Crowley and Irwin Lucki
Pages: 157-169 (13)
Animal Models of Depressive Illness: The Importance of Chronic Drug Treatment
[ Vol. 11 , Issue. 2 ]
Author(s): P. J. Mitchell and P. H. Redfern
Pages: 171-203 (33)
The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
[ Vol. 11 , Issue. 2 ]
Author(s): Robert H. Ring
Pages: 205-225 (21)
Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion
[ Vol. 11 , Issue. 2 ]
Author(s): M. A. Demitrack
Pages: 227-231 (5)
Hypericin - The Facts About a Controversial Agent
[ Vol. 11 , Issue. 2 ]
Author(s): A. Kubin, F. Wierrani, U. Burner, G. Alth and W. Grunberger
Pages: 233-253 (21)
History Repeats Itself: Pharmacodynamic Trends in the Treatment of Anxiety Disorders
[ Vol. 11 , Issue. 2 ]
Author(s): T. L. Schwartz, N. Nihalani, M. Simionescu and G. Hopkins
Pages: 255-263 (9)
Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions
[ Vol. 11 , Issue. 2 ]
Author(s): Eric X. Chen and Lillian L. Siu
Pages: 265-272 (8)
Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
[ Vol. 11 , Issue. 2 ]
Author(s): Ritu Saini, William D. Tutrone and Jeffrey M. Weinberg
Pages: 273-280 (8)